Inhalation Research Services signs CRO contract worth over 1 million SEK with US pharma company

Report this content

(Stockholm July 5, 2021) Inhalation Research Services (IRS), ISAB’s contract research organization, has signed a contract worth 101 000 EURO (just over 1 million SEK) with a US pharma company. This is the first contract following ISAB’s recent agreements with US lead generating agents specializing in inhalation drug development. If successful, the proof-of-concept research project is expected to lead to a purchase order for the entire PreciseInhale® system and its new mouse exposure module.

The new IRS project is for an innovative US pharma company that is developing novel mRNA therapies for the treatment of cystic fibrosis and other pulmonary diseases. The contract is the first materialized purchase order following ISAB signing new lead generating  agreements for the US market at the end of April 2021. The research project is being seen as a proof-of-concept study, with the client potentially purchasing the entire PreciseInhale® system and the new mouse exposure module, if successful.

The contract is also the first ISAB has received for its in vivo mouse module, in which the animal is intubated tracheally, bypassing the nose and ensuring inhalation direct to the lung. This method significantly reduces the risk of substance losses and enables active, precise control of the dose delivered - providing Particle Size Distribution lung data closely resembling clinical data.

CEO Manoush Masarrat: “We are delighted to start on this new partnership, the US is a hugely important market for us, and this is fantastic validation of the increased strategic sales and commercialization activities we’ve embarked on recently – with our lead generating partners in the US. It confirms yet again how much pharma companies can de-risk their research with our unique equipment. We look forward to our new relationships and partnerships in the US continuing to bear fruit.

For more information on Inhalation Sciences, please contact:

Manoush Masarrat, CEO


Mobile: +46 (0)73 628 9153

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.

The information above was provided by Inhalation Sciences Sweden AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on July 5, 0830, 2021.